Cyclophosphamide in chronic progressive multiple sclerosis: A comparative study

L. La Mantia, M. Eoli, A. Salmaggi, V. Torri, C. Milanese

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

No effective treatment is presently available for progressive multiple sclerosis (MS). Cyclophosphamide (CFX), a cytotoxic immunosuppressive drug widely used in systemic dysimmune diseases, has been proposed for the treatment of multiple sclerosis with different schedules and controversial results. To evaluate the safety and clinical efficacy of CFX, we compared three different treatment schedules in patients with progressive MS: induction followed by bimonthly boosters for one year (17 patients); bimonthly boosters for one year without previous induction (15 patients); and monthly boosters for one year (21 patients). Survival analysis showed that the percentage of stable patients was significantly higher in the first and third treatment schedule groups. Myelotoxicity occurred in patients treated with induction and boosters (Group A). A high incidence of broncopneumonia was observed in patients undergoing the second treatment schedule (Group B). No major effects were observed in patients treated with monthly boosters (Group C). Response to treatment was limited to secondary progressive form. This study suggests that monthly treatment with CFX might be safely administered in progressive MS patients; its clinical efficacy must be confirmed by an appropriately designed clinical trials.

Original languageEnglish
Pages (from-to)32-36
Number of pages5
JournalItalian Journal of Neurological Sciences
Volume19
Issue number1
Publication statusPublished - 1998

Fingerprint

Chronic Progressive Multiple Sclerosis
Cyclophosphamide
Multiple Sclerosis
Appointments and Schedules
Therapeutics
Immunosuppressive Agents
Survival Analysis
Clinical Trials
Safety
Incidence

Keywords

  • Cyclophosphamide
  • Progressive multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Cyclophosphamide in chronic progressive multiple sclerosis : A comparative study. / La Mantia, L.; Eoli, M.; Salmaggi, A.; Torri, V.; Milanese, C.

In: Italian Journal of Neurological Sciences, Vol. 19, No. 1, 1998, p. 32-36.

Research output: Contribution to journalArticle

@article{2ad41eef6093474ea74f7fc86cadbc69,
title = "Cyclophosphamide in chronic progressive multiple sclerosis: A comparative study",
abstract = "No effective treatment is presently available for progressive multiple sclerosis (MS). Cyclophosphamide (CFX), a cytotoxic immunosuppressive drug widely used in systemic dysimmune diseases, has been proposed for the treatment of multiple sclerosis with different schedules and controversial results. To evaluate the safety and clinical efficacy of CFX, we compared three different treatment schedules in patients with progressive MS: induction followed by bimonthly boosters for one year (17 patients); bimonthly boosters for one year without previous induction (15 patients); and monthly boosters for one year (21 patients). Survival analysis showed that the percentage of stable patients was significantly higher in the first and third treatment schedule groups. Myelotoxicity occurred in patients treated with induction and boosters (Group A). A high incidence of broncopneumonia was observed in patients undergoing the second treatment schedule (Group B). No major effects were observed in patients treated with monthly boosters (Group C). Response to treatment was limited to secondary progressive form. This study suggests that monthly treatment with CFX might be safely administered in progressive MS patients; its clinical efficacy must be confirmed by an appropriately designed clinical trials.",
keywords = "Cyclophosphamide, Progressive multiple sclerosis",
author = "{La Mantia}, L. and M. Eoli and A. Salmaggi and V. Torri and C. Milanese",
year = "1998",
language = "English",
volume = "19",
pages = "32--36",
journal = "Italian Journal of Neurological Sciences",
issn = "0392-0461",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Cyclophosphamide in chronic progressive multiple sclerosis

T2 - A comparative study

AU - La Mantia, L.

AU - Eoli, M.

AU - Salmaggi, A.

AU - Torri, V.

AU - Milanese, C.

PY - 1998

Y1 - 1998

N2 - No effective treatment is presently available for progressive multiple sclerosis (MS). Cyclophosphamide (CFX), a cytotoxic immunosuppressive drug widely used in systemic dysimmune diseases, has been proposed for the treatment of multiple sclerosis with different schedules and controversial results. To evaluate the safety and clinical efficacy of CFX, we compared three different treatment schedules in patients with progressive MS: induction followed by bimonthly boosters for one year (17 patients); bimonthly boosters for one year without previous induction (15 patients); and monthly boosters for one year (21 patients). Survival analysis showed that the percentage of stable patients was significantly higher in the first and third treatment schedule groups. Myelotoxicity occurred in patients treated with induction and boosters (Group A). A high incidence of broncopneumonia was observed in patients undergoing the second treatment schedule (Group B). No major effects were observed in patients treated with monthly boosters (Group C). Response to treatment was limited to secondary progressive form. This study suggests that monthly treatment with CFX might be safely administered in progressive MS patients; its clinical efficacy must be confirmed by an appropriately designed clinical trials.

AB - No effective treatment is presently available for progressive multiple sclerosis (MS). Cyclophosphamide (CFX), a cytotoxic immunosuppressive drug widely used in systemic dysimmune diseases, has been proposed for the treatment of multiple sclerosis with different schedules and controversial results. To evaluate the safety and clinical efficacy of CFX, we compared three different treatment schedules in patients with progressive MS: induction followed by bimonthly boosters for one year (17 patients); bimonthly boosters for one year without previous induction (15 patients); and monthly boosters for one year (21 patients). Survival analysis showed that the percentage of stable patients was significantly higher in the first and third treatment schedule groups. Myelotoxicity occurred in patients treated with induction and boosters (Group A). A high incidence of broncopneumonia was observed in patients undergoing the second treatment schedule (Group B). No major effects were observed in patients treated with monthly boosters (Group C). Response to treatment was limited to secondary progressive form. This study suggests that monthly treatment with CFX might be safely administered in progressive MS patients; its clinical efficacy must be confirmed by an appropriately designed clinical trials.

KW - Cyclophosphamide

KW - Progressive multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=0031797485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031797485&partnerID=8YFLogxK

M3 - Article

C2 - 10935857

AN - SCOPUS:0031797485

VL - 19

SP - 32

EP - 36

JO - Italian Journal of Neurological Sciences

JF - Italian Journal of Neurological Sciences

SN - 0392-0461

IS - 1

ER -